Biotech ETFs: XBI vs IBB vs ARKG Compared

You want biotech exposure, but you don’t want to bet your money on a single PDUFA date. This site’s entire thesis is stock-picking binary catalysts, so here’s the honest answer the rest of the site doesn’t want to give you: for most beginners, an ETF is the right call. The problem is that the three big biotech ETFs are not interchangeable. Two “biotech ETFs” can diverge by 20 points in a single year, because they’re built completely differently.

The solution is to match the ETF’s construction to your risk tolerance. XBI is equal-weight and volatile, IBB is mega-cap and stable, and ARKG is an active genomics bet. The construction matters more than the expense ratio.

Step 1: Understand what you’re actually buying

XBI (SPDR S&P Biotech ETF) is equal-weight, which means every one of its roughly 130 holdings gets the same allocation, about 0.7% each. That tilts it toward small and mid-cap names, the ones with the binary catalysts. IBB (iShares Nasdaq Biotech ETF) is market-cap-weighted, so its biggest holdings are Amgen, Gilead, Vertex, and Regeneron, mega-cap companies with real revenue. ARKG (ARK Genomic Revolution ETF) is actively managed, meaning a human picks the stocks, with a tilt toward CRISPR, gene editing, and genomics platforms. It’s run by Cathie Wood’s ARK Invest, and its top holdings have historically included names like CRISPR Therapeutics, Intellia, and Twist Bioscience, companies that are pre-revenue or barely profitable and priced on the future of the technology. Three funds, three completely different bets.

Step 2: Know the one number that explains the divergence

Equal-weight versus cap-weight is the distinction that explains the divergence, and it’s the one beginners miss. In a cap-weight fund like IBB, the biggest companies dominate, so a 20% move in a $10 billion small cap barely moves the fund. In an equal-weight fund like XBI, that same small cap moves the fund meaningfully. That’s why XBI is far more volatile than IBB, and why XBI can fall 63.89% peak-to-trough (February 2021 to May 2022) while holding the same broad sector. XBI and IBB hold many of the same tickers; what differs is the weight, and the weight is the entire ballgame.

Step 3: Check the expense ratio, but don’t overpay for the argument

XBI charges about 0.35%, IBB about 0.45%, and ARKG about 0.75%. Over a decade, the difference between 0.35% and 0.75% compounds, but it’s secondary to the construction difference. The bigger cost is active management: ARKG charges more because a human picks the stocks, and active biotech management has historically underperformed the index it’s trying to beat. Pay for construction, not for stock-picking confidence. The fee drag is real but slow: on a $10,000 investment earning 8% a year, the difference between a 0.35% and a 0.75% fee compounds to roughly $3,000 over 20 years. Meaningful, but far smaller than the gap between owning the equal-weight and cap-weight versions of the same sector.

Step 4: Accept that an ETF removes single-stock risk, not sector risk

An ETF diversifies away the binary risk of one drug failing. It does not remove the sector’s risk. XBI fell 63.89% in the 2021-2022 biotech bear market, driven by the fastest Federal Reserve rate-hiking cycle in 40 years. Owning the whole sector did not save you from the sector’s drawdown. Volatility cuts both ways, which is why XBI also posted a 72% gain in the 12 months through July 2026. An ETF doesn’t smooth the ride; it just removes the single-name blow-up risk. This is the core lesson from the guide on building a biotech portfolio that survives CRLs.

Step 5: Know when to skip the ETF and buy stocks

An ETF gives you diversified beta. It cannot give you the 3-5x moves a single name delivers when a trial hits. If you’re willing to do the work, reading trial designs and catalysts, individual names offer upside an ETF structurally cannot capture. The guides to reading clinical trial statistics and trading FDA catalysts are the work that justifies picking stocks over funds. That work is real: reading the trial design, checking the primary endpoint, and knowing the PDUFA date before you size a position.

Step 6: Use the barbell

The structure that fits both personas is a barbell: a core position in an ETF (the boring, diversified base) plus a small satellite sleeve of individual catalyst stocks. The core keeps you invested through the volatility; the satellite gives you exposure to the asymmetric upside. For the satellite names, start with the ranked list of 2026 catalysts.

Step 7: Mind tax and liquidity, but don’t overthink them

ETFs are more tax-efficient than actively trading single names, because low turnover means fewer taxable events. And ETF bid-ask spreads matter less than the spreads on small-cap biotech names, which can be wide. These are second-order considerations. Construction, drawdown tolerance, and your willingness to do the work come first.

Common mistakes

Buying ARKG because it’s “the genomics ETF” without realizing you’re paying 0.75% for a human’s bets that have historically lagged.

Assuming any biotech ETF is diversified enough to be safe. XBI fell 63.89% peak-to-trough; diversification reduced single-name risk, not sector risk.

Picking the cheapest ETF without checking the construction. The 0.10% expense difference between XBI and IBB is trivial next to the fact that one holds 130 equal-weight names and the other is dominated by four mega-caps.

Selling the ETF to chase a catalyst you read about. If you want catalyst upside, size a satellite sleeve for it; don’t gut the diversified core.

Final checklist

Before you buy a biotech ETF, answer four questions. What’s the construction: equal-weight, cap-weight, or active? What drawdown can you actually stomach, because XBI has shown you 63.89%? Are you paying for construction, or for a human’s stock-picking? And do you have the appetite for the single-stock work that justifies a satellite sleeve? Answer those honestly and the right fund picks itself. Re-check the holdings and the expense ratio once a year, because fund construction and fees drift, and a fund you picked for its equal-weight exposure can quietly change its mandate. For the full beginner’s path into the sector, start with how to invest in biotech stocks.